Accepted Article Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: an analysis from the OpT2mise randomized trial Muriel METZGER, 1 Javier CASTAÑEDA, 2 Yves REZNIK, 3 Francesco GIORGINO, 4 Ignacio CONGET, 5 Ronnie ARONSON, 6 Simona DE PORTU, 7 Sarah RUNZIS, 7 Scott W LEE, 8 Ohad COHEN 9 1 Diabetes Clinic, Jerusalem, Israel; 2 Medtronic Bakken Research Center, Maastricht, The Netherlands; 3 Department of Endocrinology, University of Caen Côte de Nacre Regional Hospital Center, Caen, France; 4 Department of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy; 5 Diabetes Unit, Endocrinology and Nutrition Department, University Hospital Clinic, Barcelona, Spain; 6 LMC Diabetes & Endocrinology, Toronto, Ontario, Canada; 7 Medtronic International Trading Sàrl, Tolochenaz, Switzerland; 8 Medtronic Diabetes, Northridge, California, USA; 9 Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel Running title: Predictors of glycemic control with CSII Address for correspondence: Ohad Cohen M.D. , Institute of Endocrinology, Chaim Sheba Medical Center, Tel Hashomer, Israel Ohad.cohen@sheba.health.gov.il Source of funding: The study was sponsored by Medtronic International Trading Sàrl,Tolochenaz, Switzerland. Keywords: Blood glucose self-monitoring; glycated hemoglobin; insulin infusion systems; insulin therapy; multiple daily injections; type 2 diabetes mellitus This article is protected by copyright. All rights reserved. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.12960